Orthocell has announced the successful completion of the first Remplir™ surgical case in Hong Kong and the official launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of Hong Kong.
Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBone™.
Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.
Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.
Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.
Orthocell has identified a promising new application for its flagship Remplir™ nerve repair device – for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP).
Orthocell has today released interim results from a new Remplir™ Real World Evidence study, demonstrating an overall treatment success rate of 81.1% following nerve repair procedures.